✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Amphetamineis the generic ingredient in thirty-one branded drugs marketed by Neos Theraps Inc, Neos Theraps, Teva, Rhodes Pharms, Takeda Pharms Usa, Ascent Pharms Inc, Lannett Co Inc, Actavis Elizabeth, Ani Pharms, Aurolife Pharma Llc, Elite Labs Inc, Impax Labs, Nesher Pharms, Par Pharm Inc, Specgx Llc, Sun Pharm Industries, Teva Pharms Usa, Barr Labs Inc, Teva Womens, Accord Hlthcare, Alvogen, Barr, Cediprof Inc, Epic Pharma Llc, Granules, Mylan, Nuvo Pharm, Sandoz, Teva Pharms, Uspharma Windlas, Zydus Pharms, Ucb Inc, Azurity, Alkem Labs Ltd, Amneal Pharms, Bionpharma Inc, Cerovene Inc, Glenmark Pharms Ltd, Lannett, Mayne Pharma, Novast Labs, Prinston Inc, Senores Pharms, Sun Pharm Inds Inc, Arbor Pharms Llc, and Tris Pharma Inc, and is included in sixty-four NDAs. There are eighteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Amphetamine has two patent family members in two countries.
There are fifty-five drug master file entries for amphetamine. One supplier is listed for this compound.
Summary for amphetamine
|Drug Master File Entries:||55|
|Finished Product Suppliers / Packagers:||1|
|Raw Ingredient (Bulk) Api Vendors:||30|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price trends for amphetamine|
|Drug Sales Revenues:||Drug sales revenues for amphetamine|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for amphetamine|
|What excipients (inactive ingredients) are in amphetamine?||amphetamine excipients list|
|DailyMed Link:||amphetamine at DailyMed|
Recent Clinical Trials for amphetamine
Identify potential brand extensions & 505(b)(2) entrants
|University of Alabama at Birmingham||Phase 4|
|University of California, San Francisco||Phase 2|
|University of California, Los Angeles||Early Phase 1|
Pharmacology for amphetamine
|Drug Class||Central Nervous System Stimulant |
|Physiological Effect|| Central Nervous System Stimulation |
Medical Subject Heading (MeSH) Categories for amphetamine
|Country||Patent Number||Title||Estimated Expiration|
|European Patent Office||2726066||FORMES POSOLOGIQUES POUR ADMINISTRATION ORALE ET MÉTHODES DE TRAITEMENT LES UTILISANT (DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME)||See Plans and Pricing|
|World Intellectual Property Organization (WIPO)||2013003622||See Plans and Pricing|
|>Country||>Patent Number||>Title||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.